Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
NCT03213652 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- April 17, 2018
- Completion date
- October 5, 2027
- Enrollment
- 13 (actual)
- Sites
- 126
Conditions
As the registry lists them; a condition with its own page is linked.
advanced malignant solid neoplasm, malignant solid neoplasm, recurrent ependymoma, recurrent ewing sarcoma/peripheral primitive neuroectodermal tumor, recurrent hepatoblastoma, recurrent langerhans cell histiocytosis, recurrent malignant germ cell tumor, recurrent malignant glioma, recurrent malignant solid neoplasm, recurrent medulloblastoma, recurrent neuroblastoma, recurrent non-hodgkin lymphoma, recurrent osteosarcoma, recurrent primary central nervous system neoplasm, recurrent rhabdoid tumor, recurrent rhabdomyosarcoma, recurrent soft tissue sarcoma, refractory ependymoma, refractory ewing sarcoma/peripheral primitive neuroectodermal tumor, refractory hepatoblastoma, refractory langerhans cell histiocytosis, refractory malignant germ cell tumor, refractory malignant glioma, refractory malignant solid neoplasm, refractory medulloblastoma, refractory neuroblastoma, refractory non-hodgkin lymphoma, refractory osteosarcoma, refractory primary central nervous system neoplasm, refractory rhabdoid tumor, refractory rhabdomyosarcoma, refractory soft tissue sarcoma, wilms tumor